Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1997;95:69-75

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamarche, B.
Right arrow Articles by Despres, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamarche, B.
Right arrow Articles by Despres, J.-P.

(Circulation. 1997;95:69-75.)
© 1997 American Heart Association, Inc.


Articles

Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men

Prospective Results From the Quebec Cardiovascular Study

Benoit Lamarche, PhD; Andre Tchernof, PhD; Sital Moorjani, PhD{dagger}; Bernard Cantin, MD; Gilles R. Dagenais, MD; Paul J. Lupien, MD; Jean-Pierre Despres, PhD

the Lipid Research Center, CHUL Research Center (B.L., A.T., S.M., B.C., P.J.L., J.-P.D.) and the Department of Medicine, University of Montreal (G.R.D.), Quebec, Canada.

Correspondence to Jean-Pierre Despres, PhD, Director and Professor, Lipid Research Center, CHUL Research Center, 2705 Laurier Blvd, Ste-Foy, Quebec, G1V 4G2 Canada. E-mail jpierre.despres@crchul.ulaval.ca.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Case-control studies have reported that patients with ischemic heart disease (IHD) have a higher proportion of small, dense LDL particles than do healthy control subjects. The extent to which the risk attributed to small LDL particles may be independent of concomitant variations in plasma lipoprotein-lipid concentrations remains to be clearly determined, however, particularly through prospective studies.

Methods and Results Baseline characteristics were obtained in 2103 men initially free of IHD, among whom 114 developed IHD during a 5-year follow-up period. These 114 case patients were matched with healthy control subjects for age, body mass index, smoking habits, and alcohol intake. LDL peak particle diameter (PPD) was measured a posteriori in 103 case-control pairs by nondenaturing gradient gel electrophoresis of whole plasma. Conditional logistic regression analysis of the case-control status revealed that men in the first tertile of the control LDL-PPD distribution (LDL-PPD<=25.64 nm) had a 3.6-fold increase in the risk of IHD (95% CI, 1.5 to 8.8) compared with those in the third tertile (LDL-PPD>26.05 nm). Statistical adjustment for concomitant variations in LDL cholesterol, triglycerides, HDL cholesterol, and apolipoprotein B concentrations had virtually no impact on the relationship between small LDL particles and the risk of IHD.

Conclusions These results represent the first prospective evidence suggesting that the presence of small, dense LDL particles may be associated with an increased risk of subsequently developing IHD in men. Results also suggest that the risk attributed to small LDL particles may be partly independent of the concomitant variation in plasma lipoprotein-lipid concentrations.


Key Words: apolipoproteins • lipids • heart diseases • risk factors • lipoproteins


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Although the association between LDL cholesterol levels and IHD is well accepted, a relatively high proportion of patients with IHD have plasma LDL cholesterol levels in the normal range.1 LDL particles are heterogeneous with respect to size, density, composition, and physicochemical properties.2 3 4 5 Several approaches have been used to characterize LDL particles. Using gradient gel electrophoretic analysis of isolated LDL, Austin et al6 dichotomized LDL particles into two distinct LDL phenotypes: pattern B, with a predominance of small, dense LDL particles, and pattern A, with a higher proportion of large, more buoyant LDL particles. Others have developed a global score representative of the distribution of LDL particle size and density values.7 8 9 10 Irrespective of the approach used to characterize LDL particles and of the case definition, dense LDL particles were more prevalent among IHD case patients than among IHD-free control subjects.10 11 12 13 In some instances, the relationship between the dense LDL phenotype and IHD remained significant after control for age, degree of obesity, and sex.14 15

An increased proportion of small, dense LDL particles has also been associated with marked alterations in plasma lipoprotein and lipid levels, such as elevated TG and apo B concentrations and reduced HDL cholesterol levels, all of which are highly predictive of an increased risk for IHD.8 10 13 14 15 16 Whether the increased IHD risk associated with the presence of small, dense LDL is independent of the concomitant variation in plasma lipid levels remains to be clearly established, particularly through prospective studies.17 The respective contributions of the dense LDL phenotype and of lipoprotein-lipid levels to the subsequent development of IHD were examined in a subsample of men involved in the prospective phase of the Quebec Cardiovascular Study. The LDL phenotype was determined by measurement of LDL-PPD in men initially free of clinical manifestations of IHD at entry, who eventually developed IHD over a 5-year follow-up. These men were compared with a group of matched control subjects who remained free of IHD during the same period.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Study Population and Follow-up
The Quebec Cardiovascular Study cohort has been described in detail previously.18 19 Briefly, in 1973 a random sample of 4637 men 35 to 64 years old was recruited by use of the provincial electoral lists from seven counties of the Quebec metropolitan area for an evaluation of cardiovascular risk factors. Subsequent evaluations were performed at regular intervals, and data collected in 1985 were used as the baseline characteristics for the present prospective analyses. At the 1985 evaluation, 61% (n=2443) of the living cohort came to the lipid clinic in a fasting state for their evaluation. Among the 1557 other living potential participants, 10% could not be located, 19% showed up in a nonfasting state, and 71% either refused to participate or were evaluated in a nonfasting state at their homes by nurses of the project. Analyses of data collected in 1973 revealed that the age distribution of the 2443 participating men in 1985 was representative of the original cohort. In 1990 to 1991, all participants were contacted by mail and invited to answer a short standardized questionnaire on smoking habits, medication use, and history of cardiovascular diseases and diabetes mellitus. For those who reported such diseases and those who had died, hospital charts were reviewed. Telephone calls were made to participants who did not answer a second letter or, if unsuccessful, to a close family member. Mortality and morbidity data were obtained in 99% and 96%, respectively, of the participants of the 1973 initial screening. No difference in the frequency of IHD mortality was observed between the participants and the nonparticipants.

Evaluation of Risk Factors
Data on demographic and lifestyle variables as well as medical history and medication were obtained in 1985 through a standardized questionnaire administered to each participant by trained nurses and further reviewed by a physician. Body weight and height were recorded. Resting blood pressure was measured after a 5-minute rest in a sitting position. The mean of two blood pressure measures taken 5 minutes apart was used in the analyses. The following data were compiled from the questionnaire: personal and family history of IHD and diabetes, smoking habits, alcohol consumption, and medication use. Diabetes was considered in men who self-reported the disease or who were treated with hypoglycemic agents. Only 2% of men were using hypolipidemic drugs in 1985, whereas 8% and 4% of men, respectively, were using ß-blockers and diuretics on a regular basis at the 1985 screening. Alcohol intake was computed from the type of beverage (beer, wine, and spirits) consumed in ounces per week and then standardized as absolute quantity, 1 oz of absolute alcohol being equivalent to 22.5 g of alcohol. Family history of IHD was considered positive if at least one parent and/or one sibling had a previous history of IHD.

Definition of IHD Events
The diagnosis of a first IHD event included typical effort angina, coronary insufficiency, nonfatal myocardial infarction, and coronary death. All myocardial infarction case patients met the criteria previously described,18 namely, diagnostic ECG changes alone or two of the following criteria: typical chest pain of >=20 minutes' duration, abnormal creatine kinase enzyme at least twice the upper limit of normal, or characteristic ECG changes. Coronary insufficiency was considered if typical retrosternal chest pain of at least 15 minutes' duration was associated with transient ischemic ECG changes but without significant elevation in levels of creatine kinase. Diagnoses of all myocardial infarctions and coronary insufficiency were confirmed by hospital charts. All ECGs were read by the same cardiologist, who was unaware of the participants' risk profile. The diagnosis of effort angina was based on typical symptoms of retrosternal squeezing or pressure-type discomfort occurring on exertion and relieved by rest and/or nitroglycerin. Criteria for the diagnosis of coronary deaths included confirmation from death certificates, or autopsy report confirming the presence of coronary disease and without evidence for noncardiac disease that could explain death. Myocardial infarction was considered fatal if death occurred within 4 weeks of the initial event or if it was diagnosed at autopsy. IHD-related deaths were confirmed from the Provincial Death Registry. Informed consent was obtained to review relevant hospital files. Autopsies were performed in about one third of deaths.

Pairing Procedures
From the sample of 2103 men without clinical evidence of IHD in 1985 and with a complete profile, 114 developed IHD during the 5-year follow-up that ended in September 1990.19 The 114 cases of IHD included 48 first cases of myocardial infarction, 51 cases of effort angina, and 15 IHD-related deaths. Each subject with confirmed IHD (case subject) was matched with a control subject selected among the remaining 1989 men who showed no clinical signs of IHD during follow-up.20 Subjects were matched on the basis of age, cigarette smoking, body mass index, and weekly alcohol intake. The mean within-pair differences for matching were 0.6 year, 0.2 kg/m2, and 0.2 oz/wk for age, body mass index, and alcohol intake, respectively. The mean within-pair difference for cigarette smoking was 0.3 cigarette per day. A total of 11 pairs of men were excluded because of the impossibility of measuring LDL size or because they could not be matched owing to extreme values of cigarettes smoked per day.

Laboratory Analyses
Twelve-hour fasting blood samples were obtained from an antecubital vein while participants were in a sitting posture. A tourniquet was used but was released before blood withdrawal into vacuum tubes (Vacutainer, Becton-Dickinson) containing EDTA. Plasma was separated from blood cells by centrifugation and was immediately used for lipid and apolipoprotein measurements. Aliquots of fasting plasma were frozen at the time of collection and were later used for the assessment of LDL size. Plasma cholesterol and TG levels were determined on an Auto Analyzer II (Technicon Instruments Corp) as previously described.21 HDL cholesterol was measured in the supernatant fraction after precipitation of apo B–containing lipoproteins with heparin–manganese chloride.22 LDL cholesterol levels were estimated by the equation of Friedewald et al,23 since men with TG levels >4.5 mmol/L were excluded from the analyses. Plasma apo B levels were measured by the rocket immunoelectrophoresis method of Laurell24 as previously described.21 The coefficients of variation for cholesterol, HDL cholesterol, TG, and apo B measurements were all <3%.

Determination of LDL-PPD
Nondenaturing 2% to 16% PAGE was performed on whole plasma according to the procedures described by Krauss and Burke2 and McNamara et al.16 Gels were prepared in our laboratory as previously described.25 Aliquots of 7.5 µL of plasma samples were applied on gels in a final concentration of 20% sucrose and 0.25% bromphenol blue. After a 15-minute prerun, electrophoresis was performed at 200 V for 12 to 16 hours and at 400 V for 2 to 4 hours. Gels were stained according to standardized procedures and stored in a 9% acetic acid/20% methanol solution until analysis with an optical densitometric image analyzer (BioImage Visage 110) coupled to a SPARC Station 2 Sun computer (Millipore) and GEL 1D software. LDL-PPD was obtained from the migration of standards of known diameter such as ferritin, thyroglobulin, and 38.0-nm latex beads (Duke Scientific Corp) and plasma standards kindly provided by Dr R.M. Krauss. The estimated diameter for the major peak in each scan was identified as the LDL-PPD. One assay of LDL-PPD was performed for each subject. Analyses of pooled plasma standards revealed that the identification of the major LDL peak was highly reproducible, with an interassay coefficient of variation of <3% (unpublished data).

Statistical Analyses
LDL-PPD was measured in 103 case-control pairs. Baseline characteristics of men who developed IHD during the 5-year follow-up were compared with the characteristics of those who remained IHD-free by Student's t test for means and {chi}2 for frequency data. Variables with a skewed distribution were log-transformed. Associations among variables were assessed with the Pearson and Spearman correlation coefficients for parametric and nonparametric variables, respectively. Conditional logistic regression analysis was used to assess the association between risk factors and IHD. Preliminary analyses have shown that the relationship of plasma lipid, lipoprotein, and apo B to IHD was essentially linear across their distribution. These variables were therefore treated as continuous in logistic models. The association between LDL-PPD and IHD was investigated with the variable as continuous and also by categorization of the LDL-PPD distribution into three groups with the tertile values of the control group (25.64 and 26.05 nm) as cutoff points. The risk of IHD associated with each continuous variable was standardized as the relative odds of IHD for a 1-SD increase in the concentration of the variable. Risk of developing IHD during the 5-year follow-up period in men having small (LDL-PPD<=25.64 nm) and intermediate (25.64<LDL-PPD<=26.05 nm) LDL-PPDs at baseline was estimated as the relative risk of IHD compared with men having large LDL particles (LDL-PPD>26.05 nm) at baseline. Odds were adjusted for the potential confounding effects of diabetes mellitus, medication use, family history of IHD, and systolic blood pressure. Diabetes mellitus, medication use, and family history were treated as categorical variables (presence or absence), whereas systolic blood pressure was treated as continuous. Statistical analyses were all performed on SAS software (SAS Institute).


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Baseline characteristics of men who developed IHD (case patients) and who remained IHD-free during the five-year follow-up (control subjects) are presented in Table 1Down. Mean age was 59±7 years, and the frequency of smokers in case patients and control subjects was identical (42%). The study design also eliminated the case-control differences in body mass index and alcohol consumption. Diabetes mellitus was more prevalent in 1985 in case patients than in control subjects (14.6% versus 1%, P<.001). The baseline prevalence of men using ß-blockers and/or diuretics on a regular basis was also higher in case patients than in control subjects (18% versus 8%, P=.02). Plasma concentrations of cholesterol, LDL cholesterol, TGs, and apo B were significantly increased in case patients compared with control subjects. Case patients were also characterized by a trend for reduced HDL cholesterol levels compared with control subjects and by a higher mean total/HDL cholesterol ratio (P=.002). Systolic blood pressure was significantly higher in case patients than in control subjects (137 versus 132 mm Hg, P=.05). Although there was a trend for smaller mean LDL-PPD in case patients than in control subjects, the difference did not reach statistical significance (P=.16). The lack of difference between case patients and control subjects in mean LDL-PPD could be attributed to the fact that a few control subjects had very low LDL-PPD (<24.2 nm). As shown in Fig 1Down, however, the distribution of LDL-PPD in men who did not develop IHD during follow-up tended to be shifted toward higher values compared with the IHD case patients ({chi}2 P=.03). By definition, one third of control subjects were found in each tertile of LDL-PPD. A smaller proportion of case patients (19.4%) were found within the third tertile of the LDL-PPD distribution (large LDL particles). Similar proportions of IHD case patients and control subjects were found in tertile 2, whereas the proportion of men having LDL-PPD<=25.64 nm was higher in case patients than in control subjects (49.5% versus 34%). As shown in Fig 2Down, LDL-PPD showed relatively strong associations with TG (r=-.46, P<.001), HDL cholesterol (r=.39, P<.001), and apo B levels (r=-.25, P<.001) but showed no relation to total cholesterol (r=-.03) or LDL cholesterol (r=.01) levels. Correlation coefficients were essentially similar between case patients and control subjects.


View this table:
[in this window]
[in a new window]
 
Table 1. Baseline Characteristics of Case and Control Patients



View larger version (30K):
[in this window]
[in a new window]
 
Figure 1. Frequency distributions of LDL-PPD in 103 pairs of case patients (solid bars) and control subjects (open bars) at baseline. LDL-PPD ranged from 22.44 to 27.07 nm, and 80% of the values were within the interval of 25.0 to 26.4 nm. The frequency distributions were significantly different between the two groups (P<.03). Also presented is the proportion of case patients in each tertile of the LDL-PPD distribution of control subjects and their corresponding mean LDL-PPD (±SD). Arrows on the x axis ({uparrow}) identify the tertile values of control subjects (25.64 and 26.05 nm).



View larger version (35K):
[in this window]
[in a new window]
 
Figure 2. Correlation coefficients between the LDL-PPD and lipoprotein-lipid levels in the 103 case ({bullet})-control ({circ}) pairs.

To examine the contribution of the small, dense LDL particles to the risk of IHD, a series of multivariate logistic analyses predicting the case-control status were performed (Table 2Down). As illustrated in model 1, the presence of small LDL particles (LDL-PPD<=25.64 nm) was associated with a 3.6-fold increase in the risk of IHD (95% CI, 1.5 to 8.8) independent of the potential confounding effects of diabetes, medication use, family history of IHD, and systolic blood pressure. Further adjustment for concomitant variations in plasma LDL cholesterol (model 2), TGs (model 3), and HDL cholesterol (model 4) had very little impact on the relationship between small LDL particles and the risk of IHD. Multivariate adjustment for apo B levels (model 5) and for the total/HDL cholesterol ratio (model 6) attenuated to some extent the association between LDL-PPD and the risk of IHD, but the impact of having small LDL particles on IHD risk remained significant (2.5-fold increase in the risk of IHD; 95% CI, 1.0 to 6.6). Although no longer significant from a statistical standpoint (P=.08), the risk associated with the presence of small, dense LDL particles was not lessened when the contributions of TGs, HDL cholesterol, and apo B to the risk of IHD were simultaneously taken into account (model 7). It is also important to point out that control for the contribution of LDL-PPD did not eliminate the association between apo B, the total/HDL cholesterol ratio, and the risk of IHD, suggesting that these variables and a high proportion of small, dense LDL particles may have some impact on the risk of IHD through independent mechanisms. These multivariate analyses were also performed while tertiles of plasma lipoprotein, lipid, and apolipoprotein levels were adjusted for. Similar results were obtained, because LDL particle size remained an independent predictor of the risk of IHD after adjustment for the contribution of plasma lipid and lipoprotein levels to IHD risk when investigated as tertiles. Exclusion of diabetic individuals did not affect the relationship between the dense LDL phenotype and the risk of IHD (not shown).


View this table:
[in this window]
[in a new window]
 
Table 2. Relationship Between LDL-PPD at Baseline and the Development of IHD at Follow-up Before and After Adjustment for Concomitant Variation in Plasma Lipoprotein-Lipid and Apo B Levels: Multivariate Conditional Logistic Analysis of 103 Case-Control Pairs of Men

Additional analyses were performed after 25 pairs of individuals were eliminated in which either or both the case and the control subjects were using ß-blockers or diuretics on a regular basis at the baseline evaluation. As shown in Table 3Down, the risk associated with the presence of small LDL particles (LDL-PPD<=25.64 nm) in this subsample of men not using medication remained elevated (OR, 5.1; P<.005) and was only slightly attenuated after the individual or simultaneous contributions of plasma TGs and apo B concentrations and of the total/HDL cholesterol ratio to IHD risk were controlled for.


View this table:
[in this window]
[in a new window]
 
Table 3. Multivariate Conditional Analysis of the Association Between the LDL-PPD and the Risk of Developing IHD in 78 Case-Control Pairs of Men Not Using ß-Blockers or Diuretics at the Baseline Evaluation

Fig 3Down presents the synergy between plasma apo B levels, the total/HDL cholesterol ratio, and small, dense LDL particles on the risk of IHD. Individuals with small LDL particles in the absence of elevated apo B concentrations (apo B levels <120 mg/dL, the median value of the distribution) were not at increased risk for IHD (OR, 1.0) compared with men with larger LDL particles and with relatively low apo B levels. Elevated apo B concentrations among individuals with large LDL particles resulted in a twofold increase in IHD risk, which did not reach statistical significance (P=.14), although the number of men in this particular subgroup was limited (n=32). Among these four groups, individuals having both elevated apo B levels and small LDL particles showed the greatest increase in IHD risk (OR, 6.2; 95% CI, 2.2 to 17.4; P<.001). A similar association was observed between LDL-PPD and the total/HDL cholesterol ratio, because only men with small LDL particles and with an elevated total/HDL cholesterol ratio were at greater risk of IHD (OR, 4.9; 95% CI, 1.9 to 12.7) compared with men having both large LDL particles and a ratio <6. Terms representing potential multiplicative interactions between LDL-PPD and other lipoprotein-lipid variables were tested in the multivariate model, and no interaction reached statistical significance.



View larger version (65K):
[in this window]
[in a new window]
 
Figure 3. Odds ratios for IHD and probability levels (top of bars) according to apo B levels, the total/HDL cholesterol (C) ratio, and LDL-PPD. The median of the distribution of apo B (120 mg/dL) and the total/HDL-C ratio (6.0) were used to classify men as having low or elevated levels for these variables. For the present analysis, men with small LDL particles (LDL-PPD<=25.64 nm) were compared with those having intermediate and large LDL particles (LDL-PPD>25.64 nm). Odds ratios were obtained by use of conditional logistic regression and are adjusted for covariables.

We also investigated the relationship between the LDL-PPD as a continuous variable and the risk of IHD. A decrease of 0.65 nm (1 SD) in LDL-PPD was associated with a 35% increase in the risk of IHD (OR, 1.35; 95% CI, 0.97 to 1.89; P=.08) after adjustment for the confounding effects of diabetes, medication use, family history of IHD, and systolic blood pressure. Among lipid, lipoprotein, and apolipoprotein variables, apo B came out as the best and only significant predictor of IHD risk in multivariate stepwise logistic analyses (P=.002). LDL-PPD as a continuous variable did not contribute to the risk of IHD after the contribution of apo B levels to IHD risk had been considered.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
To the best of our knowledge, the present study is the first to have investigated the relationship between LDL-PPD and the risk of IHD using a prospective design in a population-based study. Our results are in agreement with previous case-control studies that have uniformly reported an increased prevalence of small, dense LDL particles in patients with IHD.10 11 12 13 14 15 In the two largest case-control studies involving male subjects, patients with the dense LDL phenotype were characterized by a 3-fold15 and a 4.5-fold26 increase in the risk of IHD compared with those having a higher proportion of large LDL particles. In our study, men with small LDL particles (LDL-PPD<=25.64 nm) at baseline were at greater risk for the subsequent development of IHD than were individuals with larger particles (3.6- and 5.1-fold increases in odds ratios, respectively, when medication users were included or excluded from the analyses), independent of nonlipid risk factors such as diabetes mellitus, family history of IHD, and elevated systolic blood pressure. The relationship of small LDL particles to IHD was also independent of age, body mass index, alcohol consumption, and smoking, the covariables used in the pairing procedure of case patients and control subjects. These results suggest that the prospective association between the LDL particle size and the risk of IHD appears to be essentially of the same magnitude as the relationship reported in previous case-control investigations.17

Mechanisms responsible for the atherogenicity of small, dense LDL particles remain largely unexplained.17 27 It has been suggested that part of the risk associated with smaller, denser LDL particles may be related to the close relationship between this phenotype and disturbances in plasma lipid levels predictive of an increased risk of IHD.6 11 17 27 The previous case-control reports that have compared the predictive value of the dense LDL phenotype with that of selected lipid and lipoprotein levels have in general concluded that the association between LDL phenotype and the risk of IHD was not independent of the concomitant variations in plasma TG, HDL cholesterol, or LDL cholesterol levels.10 12 14 15 Only one study reported a residual association between LDL particle size and risk of IHD after adjustment for plasma TG levels.13 In the present study, the dense LDL phenotype remained an independent predictor of IHD risk after control for variations in plasma TG, LDL cholesterol, and HDL cholesterol concentrations and for the total/HDL cholesterol ratio, particularly when patients using ß-blockers or diuretics were eliminated. These results suggest that the temporal association between the dense LDL phenotype and the risk of IHD may not be affected by differences in plasma lipoprotein and lipid levels at baseline and that small, dense LDL particles may increase the risk of IHD through additional mechanisms other than the concomitant variations in other atherogenic lipoproteins. It has been proposed that dense LDL may have lower binding affinity for the hepatic LDL apo B/E receptor.28 LDL subfractions of intermediate density, generally found at higher concentrations in normolipidemic individuals, bind with a higher affinity to the LDL receptor and are degraded at greater rates than the denser LDL subfractions.28 Denser LDL particles are also more susceptible to oxidation.29 30 31 The atherogenicity of dense LDL particles may also be related to their capacity for binding to the intimal proteoglycans.32

We have previously reported that the hyperapolipoprotein B dyslipidemia was more prevalent in men who eventually developed IHD.19 Apo B is secreted as VLDL by the liver and remains associated with the particle until its clearance from the circulation as IDL and LDL.33 There is systematically only one apo B per particle secreted,33 and most fasting apo B is found in the LDL fraction. For this reason, apo B concentration can be considered to be a crude marker of LDL particle number. In the present report, the risk associated with smaller LDL particles appeared to be independent of the concomitant variations in apo B concentrations and thereby of particle number (TableUps 2 and 3). Elevated apo B levels were also associated with an increased risk, independent of the LDL particle size. However, the presence of small LDL particles combined with elevated apo B concentrations resulted in the greatest increase (sixfold) in the risk of IHD (Fig 3Up). We also found that apo B concentration was the best metabolic predictor of IHD risk in multivariate analyses both in the present case-control analyses and in the study of the whole cohort of the Quebec Cardiovascular Study.34 These results support the hypothesis put forward by Tornvall et al11 that LDL particle number, in addition to LDL composition, may be important with respect to IHD. These results may also have rather important clinical implications. They suggest that prevention and treatment of IHD should also be focused on reducing the number of atherogenic particles rather than only altering particle size. Although favorable increases in LDL-PPD have been observed after an intensive diet and exercise training program,35 the lack of change or trivial alterations in particle size after interventions such as lipid-lowering therapy,36 37 38 diet,39 or exercise training40 may not necessarily be indicative of an inefficient treatment, particularly in situations in which plasma apo B levels are substantially reduced by such approaches.41 In this regard, a reduction in plasma apo B concentrations after a low-fat diet has been reported in subjects with the small, dense LDL phenotype.42

Summary
These prospective results from the Quebec Cardiovascular Study suggest that a significant proportion of the risk associated with the presence of small, dense LDL particles may be independent of the concomitant variations in plasma lipid concentrations. Although characterization of the LDL phenotype and the measurement of plasma lipoprotein, lipid, and apolipoprotein levels both appear to provide independent information of IHD risk, the combination of small LDL particles and elevated apo B levels represents the metabolic state most predictive of IHD.


*    Selected Abbreviations and Acronyms
 
apo = apolipoprotein
IHD = ischemic heart disease
PPD = peak particle diameter
TG = triglyceride


*    Acknowledgments
 
This study was supported by the National Health Research Development and Welfare Canada and by the Heart and Stroke Foundation of Canada. Dr Lamarche is a recipient of a fellowship from the Medical Research Council of Canada. Andre Tchernof is a recipient of the Fonds de Formation de Chercheurs et l'Aide a la Recherche–Fonds de Recherche en Sante de Quebec fellowship. The financial contribution of Fournier Pharma/Jouveinal is also gratefully acknowledged. We are grateful to Dr N. Michelle Robitaille for her important support in the data collection and to Paul-Marie Bernard for his helpful input regarding data analysis. The contribution of Louise Fleury is also gratefully acknowledged. We also thank the participants of the Quebec Cardiovascular Study, whose cooperation has made the study possible.


*    Footnotes
 
{dagger}Dr Moorjani died October 1, 1995.

Received June 17, 1996; revision received August 16, 1996; accepted August 31, 1996.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Genest JJ, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormality in men with premature coronary heart disease. J Am Coll Cardiol. 1992;19:792-802.[Abstract]

2. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104.[Abstract]

3. Lindgren FT, Jensen LC, Wills RD, Freeman NK. Flotation rate, molecular weight and hydrated densities of the low density lipoproteins. Lipids. 1969;4:337-344.[Medline] [Order article via Infotrieve]

4. Chapman MJ, Paplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442-458.[Abstract]

5. Swinkels DW, Hak-Lemmers HLM, Demacker PNM. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. J Lipid Res. 1987;28:1233-1239.[Abstract]

6. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.[Abstract/Free Full Text]

7. de Graaf J, Swinkels DW, de Haan AF, Demacker PN, Stalenhoef AF. Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families. Am J Hum Genet. 1992;51:1295-1310.[Medline] [Order article via Infotrieve]

8. Swinkels DW, Demacker PNM, Hendriks JCM, van't Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis. 1989;9:604-613.[Abstract/Free Full Text]

9. McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992;12:1284-1290.[Abstract/Free Full Text]

10. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PWF, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187-195.[Abstract/Free Full Text]

11. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 1991;90:67-80.[Medline] [Order article via Infotrieve]

12. Crouse JR, Parks JS, Schey HM. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 1985;26:566-574.[Abstract]

13. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241-253.[Medline] [Order article via Infotrieve]

14. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34:1687-1697.[Abstract]

15. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.[Abstract/Free Full Text]

16. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis. 1987;7:483-490.[Abstract/Free Full Text]

17. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol. 1994;5:395-403.[Medline] [Order article via Infotrieve]

18. Dagenais GR, Robitaille NM, Lupien PJ, Christen A, Gingras S, Moorjani S, Meyer F, Rochon J. First coronary heart disease event rates in relation to major risk factors: Quebec Cardiovascular Study. Can J Cardiol. 1990;6:274-280.[Medline] [Order article via Infotrieve]

19. Lamarche B, Despres JP, Moorjani M, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol. 1995;75:1189-1195.[Medline] [Order article via Infotrieve]

20. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ishemic heart disease. N Engl J Med. 1996;334:252-257.

21. Moorjani S, Dupont A, Labrie F, Lupien PJ, Brun LD, Gagne C, Giguere M, Belanger A. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 1987;36:244-250.[Medline] [Order article via Infotrieve]

22. Albers JJ, Warnick GR, Wiebe D, King P, Steiner P, Smith L, Breckenridge C, Chow A, Kuba K, Weidman S, Arnett H, Wood P, Shlagenhaft A. Multi-laboratory comparison of three heparin-MnCl2 precipitation procedures for estimating cholesterol in high-density lipoproteins. Clin Chem. 1978;24:323-338.

23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.[Abstract]

24. Laurell CB. Electroimmunoassay. Scand J Clin Lab Med. 1972;124:23-27.

25. Tchernof A, Lamarche B, Prud'Homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP. The dense LDL phenotype: associations with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care. 1996;19:629-637.[Abstract]

26. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PM, Schneider AE, Hales CN, Yudkin JS. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1990;33:532-537.[Medline] [Order article via Infotrieve]

27. Rajman I, Maxwell S, Cramb R, Kendall M. Particle size: the key to the atherogenic lipoprotein? Q J Med. 1994;87:709-720.[Abstract/Free Full Text]

28. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32:1741-1753.[Abstract]

29. de Graaf J, Hak Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991;11:298-306.[Abstract/Free Full Text]

30. de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalization after clofibrate treatment. Arterioscler Thromb. 1993;13:712-719.[Abstract/Free Full Text]

31. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34:295-308.[Abstract]

32. La Belle M, Krauss RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res. 1990;31:1577-1588.[Abstract]

33. Young SG. Recent progress in understanding apolipoprotein B. Circulation. 1990;82:1574-1594.[Abstract/Free Full Text]

34. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:273-278.[Abstract/Free Full Text]

35. Beard CM, Barnard RJ, Robbins DC, Ordovas JM, Schaefer EJ. Effects of diet and exercise on qualitative and quantitative measures of LDL and its susceptibility to oxidation. Arterioscler Thromb. 1996;16:201-207.[Abstract/Free Full Text]

36. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb. 1993;13:170-189.[Abstract/Free Full Text]

37. Zhao SP, Hollaar L, van't Hooft FM, Smelt AHM, Leuven JAG, van der Laarse A. Effect of simvastatin on the apparent size of LDL particles in patients with type IIb hyperlipoproteinemia. Clin Chim Acta. 1991;203:109-118.[Medline] [Order article via Infotrieve]

38. Yuan J, Tsai MY, Hewgland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991;87:147-157.[Medline] [Order article via Infotrieve]

39. Campos H, Willett WC, Peterson RM, Siles X, Bailey SM, Wilson PW, Posner BM, Ordovas JM, Schaefer EJ. Nutrient intake comparisons between Framingham and rural and urban Puriscal, Costa Rica: associations with lipoproteins, apolipoproteins, and low density lipoprotein particle size. Arterioscler Thromb. 1991;11:1089-1099.[Abstract/Free Full Text]

40. Williams PT, Krauss RM, Wood PD, Lindgren FT, Giotas C, Vranizan KM. Lipoprotein subfractions of runners and sedentary men. Metabolism. 1986;35:45-52.[Medline] [Order article via Infotrieve]

41. Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, D'Acquarica AL, Sirtori CR. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb. 1994;14:1569-1575.[Abstract/Free Full Text]

42. Dreon DM, Fernstrom HA, Miller B, Krauss RM. Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J. 1994;8:121-126.[Abstract]




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
G. Reyes-Soffer, S. Holleran, W. Karmally, C. I. Ngai, N.-T. Chen, M. Torres, R. Ramakrishnan, W. S. Blaner, L. Berglund, H. N. Ginsberg, et al.
Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus
J. Lipid Res., September 1, 2009; 50(9): 1901 - 1909.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. S. Martin, A. N. Qasim, N. N. Mehta, M. Wolfe, K. Terembula, S. Schwartz, N. Iqbal, M. Schutta, R. Bagheri, and M. P. Reilly
Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites
Diabetes, August 1, 2009; 58(8): 1887 - 1892.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. R. Superko
Advanced Lipoprotein Testing and Subfractionation Are Clinically Useful
Circulation, May 5, 2009; 119(17): 2383 - 2395.
[Full Text] [PDF]


Home page
CirculationHome page
S. Mora
Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use
Circulation, May 5, 2009; 119(17): 2396 - 2404.
[Full Text] [PDF]


Home page
Toxicol Ind HealthHome page
M Lodovici, E Bigagli, G Bardini, and C. Rotella
Lipoperoxidation and antioxidant capacity in patients with poorly controlled type 2 diabetes
Toxicology and Industrial Health, May 1, 2009; 25(4-5): 337 - 341.
[Abstract] [PDF]


Home page
Journal of Pharmacy PracticeHome page
D. S. Nuzum and T. Merz
Macrovascular Complications of Diabetes Mellitus
Journal of Pharmacy Practice, April 1, 2009; 22(2): 135 - 148.
[Abstract] [PDF]


Home page
CirculationHome page
S. Mora, J. D. Otvos, N. Rifai, R. S. Rosenson, J. E. Buring, and P. M Ridker
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women
Circulation, February 24, 2009; 119(7): 931 - 939.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. Sam, S. Haffner, M. H. Davidson, R. B. D'Agostino Sr., S. Feinstein, G. Kondos, A. Perez, and T. Mazzone
Relationship of Abdominal Visceral and Subcutaneous Adipose Tissue With Lipoprotein Particle Number and Size in Type 2 Diabetes
Diabetes, August 1, 2008; 57(8): 2022 - 2027.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. T. Durheim, C. A. Slentz, L. A. Bateman, S. K. Mabe, and W. E. Kraus
Relationships between exercise-induced reductions in thigh intermuscular adipose tissue, changes in lipoprotein particle size, and visceral adiposity
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E407 - E412.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Adiels, S.-O. Olofsson, M.-R. Taskinen, and J. Boren
Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1225 - 1236.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524.
[Full Text] [PDF]


Home page
Diabetes CareHome page
J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Diabetes Care, April 1, 2008; 31(4): 811 - 822.
[Full Text] [PDF]


Home page
Diabetes CareHome page
P. Blackburn, I. Lemieux, B. Lamarche, J. Bergeron, P. Perron, G. Tremblay, D. Gaudet, and J.-P. Despres
Type 2 Diabetes Without the Atherogenic Metabolic Triad Does Not Predict Angiographically Assessed Coronary Artery Disease in Women
Diabetes Care, January 1, 2008; 31(1): 170 - 172.
[Full Text] [PDF]


Home page
CJASNHome page
I. H. de Boer, B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum
Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 125 - 132.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
B. J. Arsenault, I. Lemieux, J.-P. Despres, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, and S. M. Boekholdt
Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study
Eur. Heart J., November 2, 2007; 28(22): 2770 - 2777.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr
Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease
J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1735 - 1741.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. D. Brunzell
Hypertriglyceridemia
N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017.
[Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
R. Ceska
Clinical implications of the metabolic syndrome
Diabetes and Vascular Disease Research, September 1, 2007; 4(3_suppl): S2 - S4.
[Abstract] [PDF]


Home page
J. Appl. Physiol.Home page
C. A. Slentz, J. A. Houmard, J. L. Johnson, L. A. Bateman, C. J. Tanner, J. S. McCartney, B. D. Duscha, and W. E. Kraus
Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount
J Appl Physiol, August 1, 2007; 103(2): 432 - 442.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. E. McBride
Triglycerides and Risk for Coronary Heart Disease
JAMA, July 18, 2007; 298(3): 336 - 338.
[Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
E. Windler, M. Schoffauer, and B.-C. Zyriax
The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 136 - 142.
[Abstract] [PDF]


Home page
HeartHome page
K. Aznaouridis, C. Vlachopoulos, I. Dima, N. Ioakeimidis, and C. Stefanadis
Triglyceride level is associated with wave reflections and arterial stiffness in apparently healthy middle-aged men
Heart, May 1, 2007; 93(5): 613 - 614.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
W. A. van der Steeg, S. M. Boekholdt, E. A. Stein, K. El-Harchaoui, E. S.G. Stroes, M. S. Sandhu, N. J. Wareham, J. W. Jukema, R. Luben, A. H. Zwinderman, et al.
Role of the Apolipoprotein B-Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk
Ann Intern Med, May 1, 2007; 146(9): 640 - 648.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. Shrestha, H. C. Freake, M. M. McGrane, J. S. Volek, and M. L. Fernandez
A Combination of Psyllium and Plant Sterols Alters Lipoprotein Metabolism in Hypercholesterolemic Subjects by Modifying the Intravascular Processing of Lipoproteins and Increasing LDL Uptake
J. Nutr., May 1, 2007; 137(5): 1165 - 1170.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Okazaki, S. Usui, A. Fukui, I. Kubota, and H. Tomoike
Component Analysis of HPLC Profiles of Unique Lipoprotein Subclass Cholesterols for Detection of Coronary Artery Disease
Clin. Chem., November 1, 2006; 52(11): 2049 - 2053.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. Shrestha, J. S. Volek, J. Udani, R. J.Wood, C. M. Greene, D. Aggarwal, J. H. Contois, B. Kavoussi, and M. L. Fernandez
A Combination Therapy Including Psyllium and Plant Sterols Lowers LDL Cholesterol by Modifying Lipoprotein Metabolism in Hypercholesterolemic Individuals
J. Nutr., October 1, 2006; 136(10): 2492 - 2497.
[Abstract] [Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
G. Steiner
Implications of the global diabetes epidemic
Diabetes and Vascular Disease Research, September 1, 2006; 3(1_suppl): S2 - S5.
[Abstract] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
P. Berhanu, M. S Kipnes, M. A Khan, A. T Perez, S. F Kupfer, R. G Spanheimer, S. Demissie, and P. R Fleck
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy
Diabetes and Vascular Disease Research, May 1, 2006; 3(1): 39 - 44.
[Abstract] [PDF]


Home page
Am. J. Clin. Nutr.Home page
R. M Krauss, P. J Blanche, R. S Rawlings, H. S Fernstrom, and P. T Williams
Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia
Am. J. Clinical Nutrition, May 1, 2006; 83(5): 1025 - 1031.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
J.-P. Despres
Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk
Eur. Heart J. Suppl., May 1, 2006; 8(suppl_B): B4 - B12.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. D. Otvos, D. Collins, D. S. Freedman, I. Shalaurova, E. J. Schaefer, J. R. McNamara, H. E. Bloomfield, and S. J. Robins
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
Circulation, March 28, 2006; 113(12): 1556 - 1563.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
E. R Christ, M. H Cummings, M. Stolinski, N. Jackson, P. J Lumb, A. S Wierzbicki, P. H Sonksen, D. L Russell-Jones, and A M. Umpleby
Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study.
Eur. J. Endocrinol., March 1, 2006; 154(3): 459 - 466.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
M. Rizzo and K. Berneis
Low-density lipoprotein size and cardiovascular risk assessment
QJM, January 1, 2006; 99(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
Evolving treatment paradigms for vascular risk reduction in type 2 diabetes: Report of an international symposium held in Barcelona, Spain, January 27-29, 2006
The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1_suppl): S1 - S12.
[PDF]


Home page
HeartHome page
Prepared by: British Cardiac Society, British Hype
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Heart, December 1, 2005; 91(suppl_5): v1 - v52.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
B. J. Kim, S. T. Hwang, K. C. Sung, B. S. Kim, J. H. Kang, M. H. Lee, and J. R. Park
Comparison of the Relationships between Serum Apolipoprotein B and Serum Lipid Distributions
Clin. Chem., December 1, 2005; 51(12): 2257 - 2263.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
I. Gazi, E. S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, and A. D. Tselepis
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma
Clin. Chem., December 1, 2005; 51(12): 2264 - 2273.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al.
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Circulation, October 25, 2005; 112(17): 2735 - 2752.
[Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Inflammation, Atherosclerosis, and Aspects of Insulin Action
Diabetes Care, September 1, 2005; 28(9): 2312 - 2319.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Petersen, M. Dyrby, S. Toubro, S. B. Engelsen, L. Norgaard, H. T. Pedersen, and J. Dyerberg
Quantification of Lipoprotein Subclasses by Proton Nuclear Magnetic Resonance-Based Partial Least-Squares Regression Models
Clin. Chem., August 1, 2005; 51(8): 1457 - 1461.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
B. G. Brown
Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy
Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F34 - F40.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
A. C. St-Pierre, B. Cantin, P. Mauriege, J. Bergeron, G. R. Dagenais, J.-P. Despres, and B. Lamarche
Insulin resistance syndrome, body mass index and the risk of ischemic heart disease
Can. Med. Assoc. J., May 10, 2005; 172(10): 1301 - 1305.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
W. S. Tzou, P. S. Douglas, S. R. Srinivasan, W. Chen, G. Berenson, and J. H. Stein
Advanced Lipoprotein Testing Does Not Improve Identification of Subclinical Atherosclerosis in Young Adults: The Bogalusa Heart Study
Ann Intern Med, May 3, 2005; 142(9): 742 - 750.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
R. H. Mackey, L. H. Kuller, K. Sutton-Tyrrell, R. W. Evans, R. Holubkov, and K. A. Matthews
Hormone Therapy, Lipoprotein Subclasses, and Coronary Calcification: The Healthy Women Study
Arch Intern Med, March 14, 2005; 165(5): 510 - 515.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw
Biochemical risk markers: a novel area for better prediction of renal risk?
Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. D. Brunzell
Increased ApoB in Small Dense LDL Particles Predicts Premature Coronary Artery Disease
Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 474 - 475.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. C. St-Pierre, B. Cantin, G. R. Dagenais, P. Mauriege, P.-M. Bernard, J.-P. Despres, and B. Lamarche
Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Quebec Cardiovascular Study
Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 553 - 559.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. M Backes and C. A Gibson
Effect of Lipid-Lowering Drug Therapy on Small-Dense Low-Density Lipoprotein
Ann. Pharmacother., March 1, 2005; 39(3): 523 - 526.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
V. Charlton-Menys and P. N. Durrington
Apolipoprotein A5 and Hypertriglyceridemia
Clin. Chem., February 1, 2005; 51(2): 295 - 297.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
I. J. Kullo and C. M. Ballantyne
Conditional Risk Factors for Atherosclerosis
Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230.
[Abstract] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Dyslipidemia and the Metabolic Syndrome
Diabetes Care, December 1, 2004; 27(12): 3009 - 3016.
[Full Text] [PDF]


Home page
CirculationHome page
W. Marz, H. Scharnagl, K. Winkler, A. Tiran, M. Nauck, B. O. Boehm, and B. R. Winkelmann
Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study
Circulation, November 9, 2004; 110(19): 3068 - 3074.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Kornerup, B. G. Nordestgaard, T. K. Jensen, B. Feldt-Rasmussen, J. P. Eiberg, K. S. Jensen, and J. S. Jensen
Transendothelial exchange of low-density lipoprotein is unaffected by the presence of severe atherosclerosis
Cardiovasc Res, November 1, 2004; 64(2): 337 - 345.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Gonzalez-Navarro, Z. Nong, M. J. A. Amar, R. D. Shamburek, J. Najib-Fruchart, B. J. Paigen, H. B. Brewer Jr., and S. Santamarina-Fojo
The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice
J. Biol. Chem., October 29, 2004; 279(44): 45312 - 45321.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Santamarina-Fojo, H. Gonzalez-Navarro, L. Freeman, E. Wagner, and Z. Nong
Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis
Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1750 - 1754.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. D. Badzioch, R. P. Igo Jr, F. Gagnon, J. D. Brunzell, R. M. Krauss, A. G. Motulsky, E. M. Wijsman, and G. P. Jarvik
Low-Density Lipoprotein Particle Size Loci in Familial Combined Hyperlipidemia: Evidence for Multiple Loci From a Genome Scan
Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1942 - 1950.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
G. Boden and M. Laakso
Lipids and Glucose in Type 2 Diabetes: What is the cause and effect?
Diabetes Care, September 1, 2004; 27(9): 2253 - 2259.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
H. C. Geiss, S. Bremer, P. H. R. Barrett, C. Otto, and K. G. Parhofer
In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis
J. Lipid Res., August 1, 2004; 45(8): 1459 - 1467.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. S. Jensen, B. Feldt-Rasmussen, K. S. Jensen, P. Clausen, H. Scharling, and B. G. Nordestgaard
Transendothelial lipoprotein exchange and microalbuminuria
Cardiovasc Res, July 1, 2004; 63(1): 149 - 154.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. C. Carr and J. D. Brunzell
Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2601 - 2607.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
B. Lamarche and S. Desroches
Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Quebec experience
Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1149S - 1152S.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
D. R. Witte, M. R. Taskinen, H. Perttunen-Nio, A. van Tol, S. Livingstone, and H. M. Colhoun
Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis
J. Lipid Res., June 1, 2004; 45(6): 1069 - 1076.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J.-C. Hogue, B. Lamarche, D. Gaudet, M. Lariviere, A. J. Tremblay, J. Bergeron, I. Lemieux, J.-P. Despres, C. Gagne, and P. Couture
Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia
J. Lipid Res., June 1, 2004; 45(6): 1077 - 1083.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Y. Bosse, L. Perusse, and M.-C. Vohl
Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations
J. Lipid Res., June 1, 2004; 45(6): 1008 - 1026.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
R. M. Krauss
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Diabetes Care, June 1, 2004; 27(6): 1496 - 1504.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
T. Teerlink, P. G. Scheffer, S. J. L. Bakker, and R. J. Heine
Combined data from LDL composition and size measurement are compatible with a discoid particle shape
J. Lipid Res., May 1, 2004; 45(5): 954 - 966.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. E. Brousseau, E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
N. Engl. J. Med., April 8, 2004; 350(15): 1505 - 1515.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Holvoet, S. B. Kritchevsky, R. P. Tracy, A. Mertens, S. M. Rubin, J. Butler, B. Goodpaster, and T. B. Harris
The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort
Diabetes, April 1, 2004; 53(4): 1068 - 1073.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A.M. Georgieva, M.M.J. van Greevenbroek, R.M. Krauss, M.C.G.J. Brouwers, V.M.M.-J. Vermeulen, M.G. Robertus-Teunissen, C.J.H. van der Kallen, and T.W.A. de Bruin
Subclasses of Low-Density Lipoprotein and Very Low-Density Lipoprotein in Familial Combined Hyperlipidemia: Relationship to Multiple Lipoprotein Phenotype
Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 744 - 749.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
G. Bos, P. G. Scheffer, D. Vieira, J. M. Dekker, G. Nijpels, M. Diamant, T. Teerlink, C. D.A. Stehouwer, L. M. Bouter, R. J. Heine, et al.
The Relationship of Lipoprotein Lipase Activity and LDL size Is Dependent on Glucose Metabolism in an Elderly Population: The Hoorn Study
Diabetes Care, March 1, 2004; 27(3): 796 - 798.
[Full Text] [PDF]


Home page
J. Nutr.Home page
S. Desroches, J.-F. Mauger, L. M. Ausman, A. H. Lichtenstein, and B. Lamarche
Soy Protein Favorably Affects LDL Size Independently of Isoflavones in Hypercholesterolemic Men and Women
J. Nutr., March 1, 2004; 134(3): 574 - 579.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. Trovati and F. Cavalot
Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20.
[Abstract] [Full Text]


Home page
J. Clin. Pathol.Home page
G Kolovou, D Daskalova, K Anagnostopoulou, I Hoursalas, V Voudris, D P Mikhailidis, and D V Cokkinos
Postprandial hypertriglyceridaemia in patients with Tangier disease
J. Clin. Pathol., December 1, 2003; 56(12): 937 - 941.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. A. Austin, K. L. Edwards, S. A. Monks, K. M. Koprowicz, J. D. Brunzell, A. G. Motulsky, M. C. Mahaney, and J. E. Hixson
Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia
J. Lipid Res., November 1, 2003; 44(11): 2161 - 2168.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
N. Barzilai, G. Atzmon, C. Schechter, E. J. Schaefer, A. L. Cupples, R. Lipton, S. Cheng, and A. R. Shuldiner
Unique Lipoprotein Phenotype and Genotype Associated With Exceptional Longevity
JAMA, October 15, 2003; 290(15): 2030 - 2040.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
S. K Fried and S. P Rao
Sugars, hypertriglyceridemia, and cardiovascular disease
Am. J. Clinical Nutrition, October 1, 2003; 78(4): 873S - 880.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. M. Sacks and H. Campos
Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4525 - 4532.
[Full Text] [PDF]


Home page
J. Nutr.Home page
W. R. Archer, B. Lamarche, A. C. St-Pierre, J.-F. Mauger, O. Deriaz, N. Landry, L. Corneau, J.-P. Despres, J. Bergeron, P. Couture, et al.
High Carbohydrate and High Monounsaturated Fatty Acid Diets Similarly Affect LDL Electrophoretic Characteristics in Men Who Are Losing Weight
J. Nutr., October 1, 2003; 133(10): 3124 - 3129.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, M. W. Baumstark, K. Krebs, H. Wieland, and W. Marz
Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study
Diabetes Care, September 1, 2003; 26(9): 2588 - 2594.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Guerin, W. Le Goff, E. Frisdal, S. Schneider, D. Milosavljevic, E. Bruckert, and M. J. Chapman
Action of Ciprofibrate in Type IIB Hyperlipoproteinemia: Modulation of the Atherogenic Lipoprotein Phenotype and Stimulation of High-Density Lipoprotein-Mediated Cellular Cholesterol Efflux
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3738 - 3746.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Holvoet, T. B. Harris, R. P. Tracy, P. Verhamme, A. B. Newman, S. M. Rubin, E. M. Simonsick, L. H. Colbert, and S. B. Kritchevsky
Association of High Coronary Heart Disease Risk Status With Circulating Oxidized LDL in the Well-Functioning Elderly: Findings From the Health, Aging, and Body Composition Study
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1444 - 1448.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. A. Kreisberg and A. Oberman
Medical Management of Hyperlipidemia/Dyslipidemia
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2445 - 2461.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
K. L. Herbst, J. K. Amory, J. D. Brunzell, H. A. Chansky, and W. J. Bremner
Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk
Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1112 - E1118.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
M.-P. St-Onge, B. Lamarche, J.-F. Mauger, and P. J. H. Jones
Consumption of a Functional Oil Rich in Phytosterols and Medium-Chain Triglyceride Oil Improves Plasma Lipid Profiles in Men
J. Nutr., June 1, 2003; 133(6): 1815 - 1820.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
A. J. Jenkins, T. J. Lyons, D. Zheng, J. D. Otvos, D. T. Lackland, D. McGee, W. T. Garvey, R. L. Klein, and The DCCT/EDIC Research Group
Serum Lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: Associations with gender and glycemia
Diabetes Care, March 1, 2003; 26(3): 810 - 818.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. C. Felmeden, C. G.C. Spencer, A. D. Blann, D. G. Beevers, and G. Y.H. Lip
Low-Density Lipoprotein Subfractions and Cardiovascular Risk in Hypertension: Relationship to Endothelial Dysfunction and Effects of Treatment
Hypertension, March 1, 2003; 41(3): 528 - 533.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. R. Holmer, C. Hengstenberg, H.-G. Kraft, B. Mayer, M. Poll, S. Kurzinger, M. Fischer, H. Lowel, G. Klein, G. A.J. Riegger, et al.
Association of Polymorphisms of the Apolipoprotein(a) Gene With Lipoprotein(a) Levels and Myocardial Infarction
Circulation, February 11, 2003; 107(5): 696 - 701.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Coll. Nutr.Home page
G. D. Kolovou, D. Ch. Daskalova, S. A. Iraklianou, E. N. Adamopoulou, N. D. Pilatis, G. C. Hatzigeorgiou, and D. V. Cokkinos
Postprandial Lipemia in Hypertension
J. Am. Coll. Nutr., February 1, 2003; 22(1): 80 - 87.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
W. T. Garvey, S. Kwon, D. Zheng, S. Shaughnessy, P. Wallace, A. Hutto, K. Pugh, A. J. Jenkins, R. L. Klein, and Y. Liao
Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance
Diabetes, February 1, 2003; 52(2): 453 - 462.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Winkler, C. Abletshauser, M. M. Hoffmann, I. Friedrich, M. W. Baumstark, H. Wieland, and W. Marz
Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5485 - 5490.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
F. R. Sattler, E. T. Schroeder, M. P. Dube, S. V. Jaque, C. Martinez, P. J. Blanche, S. Azen, and R. M. Krauss
Metabolic effects of nandrolone decanoate and resistance training in men with HIV
Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1214 - E1222.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. E. Kraus, J. A. Houmard, B. D. Duscha, K. J. Knetzger, M. B. Wharton, J. S. McCartney, C. W. Bales, S. Henes, G. P. Samsa, J. D. Otvos, et al.
Effects of the Amount and Intensity of Exercise on Plasma Lipoproteins
N. Engl. J. Med., November 7, 2002; 347(19): 1483 - 1492.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. J. Blake, J. D. Otvos, N. Rifai, and P. M Ridker
Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women
Circulation, October 8, 2002; 106(15): 1930 - 1937.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. Somekawa, H. Umeki, K. Kobayashi, S. Tomura, T. Aso, and H. Hamaguchi
Effects of Hormone Replacement Therapy and Hepatic Lipase Polymorphism on Serum Lipid Profiles in Postmenopausal Japanese Women
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4766 - 4770.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Petersen, H. Pedersen, A. Major-Pedersen, T. Jensen, and P. Marckmann
Effect of Fish Oil Versus Corn Oil Supplementation on LDL and HDL Subclasses in Type 2 Diabetic Patients
Diabetes Care, October 1, 2002; 25(10): 1704 - 1708.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Faggin, A. Zambon, M. Puato, S. S. Deeb, S. Bertocco, S. Sartore, G. Crepaldi, A. C. Pessina, and P. Pauletto
Association between the -514 c->t polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis
J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1059 - 1066.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
K. K. Berneis and R. M. Krauss
Metabolic origins and clinical significance of LDL heterogeneity
J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamarche, B.
Right arrow Articles by Despres, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamarche, B.
Right arrow Articles by Despres, J.-P.